{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:18:34Z","timestamp":1790511514718,"version":"4.1.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG042791"],"award-info":[{"award-number":["U01AG042791"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R1AG046179"],"award-info":[{"award-number":["R1AG046179"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01\/R56 AG053267"],"award-info":[{"award-number":["R01\/R56 AG053267"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG059798"],"award-info":[{"award-number":["U01AG059798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive decline and dementia onset by intervening before significant neuronal damage occurs. In recent years, the first AD prevention trials have launched and are yielding important findings on the biology of targeting asymptomatic AD pathology. However, there are limitations that impact the design of these prevention trials, including the translation of animal models that recapitulate key stages and multiple pathological aspects of the human disease, missing target validation in asymptomatic disease, uncertain causality of the association of pathophysiologic changes with cognitive and clinical symptoms, and limited biomarker validation for novel targets. The field is accelerating advancements in key areas including the development of highly specific and quantitative biomarker measures for AD pathology, increasing our understanding of the course and relationship of amyloid and tau pathology in asymptomatic through symptomatic stages, and the development of powerful interventions that can slow or reverse AD amyloid pathology. We review the current status of prevention trials and propose key areas of needed research as a call to basic and translational scientists to accelerate AD prevention. Specifically, we review (1) sporadic and dominantly inherited primary and secondary AD prevention trials, (2) proposed targets, mechanisms, and drugs including the amyloid, tau, and inflammatory pathways and combination treatments, (3) the need for more appropriate prevention animal models and experiments, and (4) biomarkers and outcome measures needed to design human asymptomatic prevention trials. We conclude with actions needed to effectively move prevention targets and trials forward.<\/jats:p>","DOI":"10.1186\/s13024-021-00467-y","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T09:03:07Z","timestamp":1626858187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["The informed road map to prevention of Alzheimer Disease: A call to arms"],"prefix":"10.1186","volume":"16","author":[{"given":"Eric","family":"McDade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Llibre-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","volume":"10","author":"DE Barnes","year":"2011","unstructured":"Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence. Lancet Neurol. 2011;10:819\u201328.","journal-title":"Lancet Neurol"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, Fr\u00f6lich L, Jack CR, Jones RW, et al. Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39. https:\/\/doi.org\/10.1186\/s13195-016-0207-9.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR3","doi-asserted-by":"publisher","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6.","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1515\/fhep-2014-0013","volume":"18","author":"J Zissimopoulos","year":"2015","unstructured":"Zissimopoulos J, Crimmins E, St. Clair P. The value of delaying Alzheimer\u2019s disease onset. Forum Health Econ Policy. 2015;18:25\u201339. https:\/\/doi.org\/10.1515\/fhep-2014-0013.","journal-title":"Forum Health Econ Policy"},{"key":"467_CR5","doi-asserted-by":"publisher","unstructured":"2016 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2016;12:459\u2013509. https:\/\/doi.org\/10.1016\/J.JALZ.2016.03.001.","DOI":"10.1016\/J.JALZ.2016.03.001"},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/joim.12199","volume":"275","author":"JC Morris","year":"2014","unstructured":"Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, et al. Harmonized diagnostic criteria for Alzheimer\u2019s disease: recommendations. J Intern Med. 2014;275:204\u201313. https:\/\/doi.org\/10.1111\/joim.12199.","journal-title":"J Intern Med"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159x15666170116143743","volume":"15","author":"R Ricciarelli","year":"2017","unstructured":"Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer\u2019s disease: it\u2019s time to change our mind. Curr Neuropharmacol. 2017;15:926. https:\/\/doi.org\/10.2174\/1570159x15666170116143743.","journal-title":"Curr Neuropharmacol"},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369:341\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1210951.","journal-title":"N Engl J Med"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med. 2019;380:1408\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1812840.","journal-title":"N Engl J Med"},{"key":"467_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2018;378:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1706441.","journal-title":"N Engl J Med"},{"key":"467_CR13","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMc1813435","volume":"380","author":"D Henley","year":"2019","unstructured":"Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer\u2019s disease. N Engl J Med. 2019;380:1483\u20135. https:\/\/doi.org\/10.1056\/NEJMc1813435.","journal-title":"N Engl J Med"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:311\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1312889.","journal-title":"N Engl J Med"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1705971.","journal-title":"N Engl J Med"},{"key":"467_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","volume":"5","author":"J Cummings","year":"2019","unstructured":"Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2019. Alzheimer\u2019s Dement Transl Res Clin Interv. 2019;5:272\u201393.","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"467_CR18","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2015.2316","volume":"313","author":"SM Berry","year":"2015","unstructured":"Berry SM, Connor JT, Lewis RJ. The Platform Trial. JAMA. 2015;313:1619. https:\/\/doi.org\/10.1001\/jama.2015.2316.","journal-title":"JAMA"},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2010","unstructured":"Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther. 2010;3:1. https:\/\/doi.org\/10.1186\/alzrt59.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach Homas G, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1.","journal-title":"Nat Med"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"E1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:E1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"key":"467_CR23","first-page":"521","volume":"16","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;16:521.","journal-title":"J Exp Med"},{"issue":"5","key":"467_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","volume":"15","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, et al. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2019;15(5):655\u201365.","journal-title":"Alzheimer\u2019s Dement"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266.","journal-title":"Alzheimers Dement"},{"key":"467_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jalz.2007.11.008","volume":"4","author":"AD Korczyn","year":"2008","unstructured":"Korczyn AD. The amyloid cascade hypothesis. Alzheimers Dement. 2008;4:176\u20138. https:\/\/doi.org\/10.1016\/j.jalz.2007.11.008.","journal-title":"Alzheimers Dement"},{"key":"467_CR27","doi-asserted-by":"publisher","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","volume":"5","author":"R Potter","year":"2013","unstructured":"Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, et al. Increased in vivo amyloid-b42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77. https:\/\/doi.org\/10.1126\/scitranslmed.3005615.","journal-title":"Sci Transl Med"},{"key":"467_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78:439\u201353. https:\/\/doi.org\/10.1002\/ana.24454.","journal-title":"Ann Neurol"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:40. https:\/\/doi.org\/10.1186\/s13024-020-00391-7.","journal-title":"Mol Neurodegener"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/neu.480250409","volume":"25","author":"MP Mattson","year":"1994","unstructured":"Mattson MP. Secreted forms of \u03b2-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J Neurobiol. 1994;25:439\u201350. https:\/\/doi.org\/10.1002\/neu.480250409.","journal-title":"J Neurobiol"},{"key":"467_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/13813450701572288","volume":"113","author":"V Rhein","year":"2007","unstructured":"Rhein V, Eckert A. Effects of Alzheimer\u2019s amyloid-beta and tau protein on mitochondrial function\u2014role of glucose metabolism and insulin signalling. Arch Physiol Biochem. 2007;113:131\u201341. https:\/\/doi.org\/10.1080\/13813450701572288.","journal-title":"Arch Physiol Biochem"},{"key":"467_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1590\/s1980-57642009dn30300003","volume":"3","author":"RV de Jesus","year":"2009","unstructured":"de Jesus RV, Guimar\u00e3es FM, Diniz BS, Forlenza OV. Neurobiological pathways to Alzheimer\u2019s disease: amyloid-beta, TAU protein or both? Dement Neuropsychol. 2009;3:188\u201394. https:\/\/doi.org\/10.1590\/s1980-57642009dn30300003.","journal-title":"Dement Neuropsychol"},{"key":"467_CR33","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362. https:\/\/doi.org\/10.1212\/01.WNL.0000159740.16984.3C.","journal-title":"Neurology"},{"key":"467_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-015-0108-3","volume":"7","author":"MR Farlow","year":"2015","unstructured":"Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, et al. Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7:1\u201313. https:\/\/doi.org\/10.1186\/s13195-015-0108-3.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3233\/JAD-150376","volume":"51","author":"F Pasquier","year":"2016","unstructured":"Pasquier F, Sadowsky C, Holstein A, Leterme GLP, Peng Y, Jackson N, et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51:1131\u201343. https:\/\/doi.org\/10.3233\/JAD-150376.","journal-title":"J Alzheimers Dis"},{"key":"467_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1304839.","journal-title":"N Engl J Med"},{"key":"467_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","volume":"8","author":"M Farlow","year":"2012","unstructured":"Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:261\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2011.09.224.","journal-title":"Alzheimers Dement"},{"key":"467_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.tins.2016.01.003","volume":"39","author":"S Bar\u00e3o","year":"2016","unstructured":"Bar\u00e3o S, Moechars D, Lichtenthaler SF, De Strooper B. BACE1 physiological functions may limit its use as therapeutic target for Alzheimer\u2019s disease. Trends Neurosci. 2016;39:158\u201369. https:\/\/doi.org\/10.1016\/j.tins.2016.01.003.","journal-title":"Trends Neurosci"},{"key":"467_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","volume":"7","author":"RS Doody","year":"2015","unstructured":"Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, et al. Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7:36. https:\/\/doi.org\/10.1186\/s13195-015-0121-6.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"E Karran","year":"2016","unstructured":"Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem. 2016;139:237\u201352. https:\/\/doi.org\/10.1111\/jnc.13632.","journal-title":"J Neurochem"},{"key":"467_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"key":"467_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37. https:\/\/doi.org\/10.1186\/alzrt269.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR43","doi-asserted-by":"publisher","unstructured":"Salloway S, Farlow M, McDade E, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med (2021). https:\/\/doi.org\/10.1038\/s41591-021-01369-8.","DOI":"10.1038\/s41591-021-01369-8"},{"issue":"1","key":"467_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","volume":"10","author":"AM Lacosta","year":"2018","unstructured":"Lacosta AM, Pascual-Lucas M, Pesini P, et al. Safety, tolerability and immunogenicity of an active anti-A\u03b2(40) vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther. 2018;10(1):12. https:\/\/doi.org\/10.1186\/s13195-018-0340-8.","journal-title":"Alzheimers Res Ther."},{"key":"467_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","volume":"10","author":"P Scheltens","year":"2018","unstructured":"Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther. 2018;10:107. https:\/\/doi.org\/10.1186\/s13195-018-0431-6.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.13583","volume":"139","author":"TE Golde","year":"2016","unstructured":"Golde TE. Overcoming translational barriers impeding development of Alzheimer\u2019s disease modifying therapies. J Neurochem. 2016;139:224\u201336.","journal-title":"J Neurochem"},{"key":"467_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer\u2019s Disease with plaques and tangles: intracellular A\u03b2 and synaptic dysfunction. Neuron. 2003;39:409\u201321. https:\/\/doi.org\/10.1016\/S0896-6273(03)00434-3.","journal-title":"Neuron"},{"key":"467_CR48","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3233\/JAD-2008-15405","volume":"15","author":"CA Colton","year":"2008","unstructured":"Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP. The effects of NOS2 gene deletion on mice expressing mutated human A\u03b2PP. J Alzheimers Dis. 2008;15:571\u201387. https:\/\/doi.org\/10.3233\/JAD-2008-15405.","journal-title":"J Alzheimers Dis"},{"key":"467_CR49","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/mp.2015.146","volume":"20","author":"M Brendel","year":"2015","unstructured":"Brendel M, Jaworska A, Herms J, Trambauer J, R\u00f6tzer C, Gildehaus F-J, et al. Monitoring of chronic \u03b3-secretase modulator treatment by serial amyloid-PET. Mol Psychiatry. 2015;20:1141.","journal-title":"Mol Psychiatry"},{"key":"467_CR50","unstructured":"Strobel G. In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned. Alzforum; 2020."},{"key":"467_CR51","unstructured":"Bowman Rogers M. Exposure, exposure, exposure? At CTAD, Aducanumab Scientists Make a Case. Alzforum; 2019."},{"key":"467_CR52","doi-asserted-by":"crossref","unstructured":"Bateman RJ, Ryan LM, Carrillo MC, Kerchner GA, Farlow MR, Salloway SP, et al. Panel Discussion: DIAN-TU Trial Collaborative Effort. 2020. https:\/\/alz.confex.com\/alz\/20amsterdam\/meetingapp.cgi\/Paper\/41133. Accessed 13 Nov 2020.","DOI":"10.1002\/alz.041133"},{"key":"467_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271\u20138.","journal-title":"Neurobiol Aging"},{"key":"467_CR54","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960\u20139. https:\/\/doi.org\/10.1097\/NEN.0b013e318232a379.","journal-title":"J Neuropathol Exp Neurol"},{"key":"467_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/wnl.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42:631\u20139. https:\/\/doi.org\/10.1212\/wnl.42.3.631.","journal-title":"Neurology"},{"key":"467_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362\u201381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7.","journal-title":"J Neuropathol Exp Neurol"},{"key":"467_CR57","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"issue":"1","key":"467_CR58","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):1683.","journal-title":"Nat Commun"},{"key":"467_CR59","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26:398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z.","journal-title":"Nat Med"},{"key":"467_CR60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","volume":"129","author":"RM Nisbet","year":"2015","unstructured":"Nisbet RM, Polanco JC, Ittner LM, G\u00f6tz J. Tau aggregation and its interplay with amyloid-\u03b2. Acta Neuropathol. 2015;129:207\u201320. https:\/\/doi.org\/10.1007\/s00401-014-1371-2.","journal-title":"Acta Neuropathol"},{"key":"467_CR61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2.","journal-title":"Nat Med"},{"key":"467_CR62","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"key":"467_CR63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41591-020-0797-4","volume":"26","author":"RJ Bateman","year":"2020","unstructured":"Bateman RJ, Barth\u00e9lemy NR, Horie K. Another step forward in blood-based diagnostics for Alzheimer\u2019s disease. Nat Med. 2020;26:314\u20136. https:\/\/doi.org\/10.1038\/s41591-020-0797-4.","journal-title":"Nat Med"},{"key":"467_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:22\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"467_CR65","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.23722","volume":"72","author":"ED Roberson","year":"2012","unstructured":"Roberson ED. Mouse models of frontotemporal dementia. Ann Neurol. 2012;72:837\u201349. https:\/\/doi.org\/10.1002\/ana.23722.","journal-title":"Ann Neurol"},{"key":"467_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.expneurol.2008.03.007","volume":"212","author":"H Rosenmann","year":"2008","unstructured":"Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol. 2008;212:71\u201384. https:\/\/doi.org\/10.1016\/j.expneurol.2008.03.007.","journal-title":"Exp Neurol"},{"key":"467_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barth\u00e9lemy","year":"2019","unstructured":"Barth\u00e9lemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer\u2019s disease. Front Aging Neurosci. 2019;11:121.","journal-title":"Front Aging Neurosci"},{"key":"467_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020;12:26. https:\/\/doi.org\/10.1186\/s13195-020-00596-4.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR69","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/ijms19041160","volume":"19","author":"M Medina","year":"2018","unstructured":"Medina M. An overview on the clinical development of Tau-based therapeutics. Int J Mol Sci. 2018;19:1160.","journal-title":"Int J Mol Sci"},{"key":"467_CR70","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1523\/JNEUROSCI.4922-11.2012","volume":"32","author":"B Zhang","year":"2012","unstructured":"Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32:3601\u201311.","journal-title":"J Neurosci"},{"key":"467_CR71","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","volume":"77","author":"RM Tsai","year":"2020","unstructured":"Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77:215\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3812.","journal-title":"JAMA Neurol"},{"key":"467_CR72","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","volume":"130","author":"J Wagner","year":"2015","unstructured":"Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015;130:619\u201331.","journal-title":"Acta Neuropathol"},{"key":"467_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13195-019-0522-z","volume":"11","author":"M Brendel","year":"2019","unstructured":"Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, et al. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer\u2019s disease tau. Alzheimers Res Ther. 2019;11:67. https:\/\/doi.org\/10.1186\/s13195-019-0522-z.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR74","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","volume":"288","author":"A Crowe","year":"2013","unstructured":"Crowe A, James MJ, Lee VM-Y, Smith AB III, Trojanowski JQ, Ballatore C, et al. Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem. 2013;288:11024\u201337.","journal-title":"J Biol Chem"},{"key":"467_CR75","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019;215:668\u201374. https:\/\/doi.org\/10.1192\/bjp.2019.76.","journal-title":"Br J Psychiatry"},{"key":"467_CR76","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","volume":"12","author":"MG Spillantini","year":"2013","unstructured":"Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609\u201322. https:\/\/doi.org\/10.1016\/S1474-4422(13)70090-5.","journal-title":"Lancet Neurol"},{"key":"467_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24:194\u2013203. https:\/\/doi.org\/10.5863\/1551-6776-24.3.194.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"467_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.23","volume":"3","author":"JM Keil","year":"2014","unstructured":"Keil JM, Seo J, Howell MD, Hsu WH, Singh RN, DiDonato CJ. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids. 2014;3:e174.","journal-title":"Mol Ther Nucleic Acids"},{"key":"467_CR79","doi-asserted-by":"publisher","first-page":"175628561875450","DOI":"10.1177\/1756285618754501","volume":"11","author":"V Parente","year":"2018","unstructured":"Parente V, Corti S. Advances in spinal muscular atrophy therapeutics. Ther Adv Neurol Disord. 2018;11:1756285618754501. https:\/\/doi.org\/10.1177\/1756285618754501.","journal-title":"Ther Adv Neurol Disord"},{"key":"467_CR80","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94:1056\u201370. https:\/\/doi.org\/10.1016\/j.neuron.2017.04.010.","journal-title":"Neuron"},{"key":"467_CR81","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9:eaag0481. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481.","journal-title":"Sci Transl Med"},{"key":"467_CR82","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/31508","volume":"393","author":"M Hutton","year":"1998","unstructured":"Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden HH, et al. Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702\u20134. https:\/\/doi.org\/10.1038\/31508.","journal-title":"Nature"},{"key":"467_CR83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature. 2017;547:185\u201390. https:\/\/doi.org\/10.1038\/nature23002.","journal-title":"Nature"},{"key":"467_CR84","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546\u201354. https:\/\/doi.org\/10.1212\/WNL.51.6.1546.","journal-title":"Neurology"},{"key":"467_CR85","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/ijms19040998","volume":"19","author":"\u00c1 Sebasti\u00e1n-Serrano","year":"2018","unstructured":"Sebasti\u00e1n-Serrano \u00c1, De Diego-Garc\u00eda L, D\u00edaz-Hern\u00e1ndez M. The neurotoxic role of extracellular TAU protein. Int J Mol Sci. 2018;19:998.","journal-title":"Int J Mol Sci"},{"key":"467_CR86","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1126\/science.aah6205","volume":"354","author":"A Ittner","year":"2016","unstructured":"Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-\u03b2 toxicity in Alzheimer\u2019s mice. Science. 2016;354:904\u20138.","journal-title":"Science"},{"key":"467_CR87","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, et al. Changes in amyloid-\u03b2 and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re2. https:\/\/doi.org\/10.1126\/scitranslmed.3006446.","journal-title":"Sci Transl Med"},{"key":"467_CR88","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jalz.2016.09.005","volume":"13","author":"J Schelle","year":"2017","unstructured":"Schelle J, H\u00e4sler LM, G\u00f6pfert JC, Joos TO, Vanderstichele H, Stoops E, et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement. 2017;13:701\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2016.09.005.","journal-title":"Alzheimers Dement"},{"key":"467_CR89","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6:eaaz2387. https:\/\/doi.org\/10.1126\/sciadv.aaz2387.","journal-title":"Sci Adv"},{"key":"467_CR90","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422\u201333.","journal-title":"Lancet Neurol"},{"key":"467_CR91","doi-asserted-by":"publisher","unstructured":"Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 2021; https:\/\/doi.org\/10.1002\/alz.12321.","DOI":"10.1002\/alz.12321"},{"key":"467_CR92","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat Med. 2020;26:1256\u201363. https:\/\/doi.org\/10.1038\/s41591-020-0938-9.","journal-title":"Nat Med"},{"key":"467_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0304-3940(95)11291-4","volume":"186","author":"H Mori","year":"1995","unstructured":"Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995;186:181\u20133.","journal-title":"Neurosci Lett"},{"key":"467_CR94","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1046\/j.1471-4159.1997.68010430.x","volume":"68","author":"GV Johnson","year":"1997","unstructured":"Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer\u2019s disease consists of proteolytically derived fragments. J Neurochem. 1997;68:430\u20133.","journal-title":"J Neurochem"},{"key":"467_CR95","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1212\/WNL.48.3.632","volume":"48","author":"D Galasko","year":"1997","unstructured":"Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer\u2019s disease. Neurology. 1997;48:632\u20135.","journal-title":"Neurology"},{"key":"467_CR96","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol. 1999;45:358\u201368. https:\/\/doi.org\/10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X.","journal-title":"Ann Neurol"},{"key":"467_CR97","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41593-018-0298-7","volume":"22","author":"H Fu","year":"2019","unstructured":"Fu H, Possenti A, Freer R, Nakano Y, Hernandez Villegas NC, Tang M, et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci. 2019;22:47\u201356.","journal-title":"Nat Neurosci"},{"key":"467_CR98","doi-asserted-by":"publisher","unstructured":"Leyns CEG, Gratuze M, Narasimhan S, Jain N, Koscal LJ, Jiang H, et al. TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci. 2019; https:\/\/doi.org\/10.1038\/s41593-019-0433-0.","DOI":"10.1038\/s41593-019-0433-0"},{"key":"467_CR99","doi-asserted-by":"publisher","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis Class of Evidence Criteria for rating therapeutic and diagnostic studies. Neurology. 2019; https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","DOI":"10.1212\/WNL.0000000000008081"},{"key":"467_CR100","doi-asserted-by":"publisher","first-page":"9736","DOI":"10.1038\/s41598-021-89004-x","volume":"11","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, et al. Highly specific and ultrasensitive plasma test detects Abeta(1\u201342) and Abeta(1\u201340) in Alzheimer\u2019s disease. Sci Rep. 2021;11:9736. https:\/\/doi.org\/10.1038\/s41598-021-89004-x.","journal-title":"Sci Rep"},{"key":"467_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00728-w","volume":"12","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Schaeverbeke JM, Verberk IMW, Gille B, De Schaepdryver M, Luckett ES, et al. Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther. 2020;12:1\u201316. https:\/\/doi.org\/10.1186\/s13195-020-00728-w.","journal-title":"Alzheimers Res Ther"},{"key":"467_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jnr.20093","volume":"77","author":"WJ Streit","year":"2004","unstructured":"Streit WJ. Microglia and Alzheimer\u2019s disease pathogenesis. J Neurosci Res. 2004;77:1\u20138. https:\/\/doi.org\/10.1002\/jnr.20093.","journal-title":"J Neurosci Res"},{"key":"467_CR103","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10787-012-0130-z","volume":"20","author":"GJ Broussard","year":"2012","unstructured":"Broussard GJ, Mytar J, Li RC, Klapstein GJ. The role of inflammatory processes in Alzheimer\u2019s disease. Inflammopharmacology. 2012;20:109\u201326. https:\/\/doi.org\/10.1007\/s10787-012-0130-z.","journal-title":"Inflammopharmacology"},{"key":"467_CR104","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0197-4580(00)00143-3","volume":"21","author":"KR Bales","year":"2000","unstructured":"Bales KR, Du Y, Holtzman D, Cordell B, Paul SM. Neuroinflammation and Alzheimer\u2019s disease: critical roles for cytokine\/A\u03b2-induced glial activation, NF-\u03baB, and apolipoprotein E. Neurobiol Aging. 2000;21:427\u201332.","journal-title":"Neurobiol Aging"},{"key":"467_CR105","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-015-0048-1","volume":"10","author":"M Malik","year":"2015","unstructured":"Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, et al. Genetics ignite focus on microglial inflammation in Alzheimer\u2019s disease. Mol Neurodegener. 2015;10:52. https:\/\/doi.org\/10.1186\/s13024-015-0048-1.","journal-title":"Mol Neurodegener"},{"key":"467_CR106","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-1326-9-33","volume":"9","author":"V Landel","year":"2014","unstructured":"Landel V, Baranger K, Virard I, Loriod B, Khrestchatisky M, Rivera S, et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:33. https:\/\/doi.org\/10.1186\/1750-1326-9-33.","journal-title":"Mol Neurodegener"},{"key":"467_CR107","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1146\/annurev.neuro.22.1.219","volume":"22","author":"F Gonz\u00e1lez-Scarano","year":"1999","unstructured":"Gonz\u00e1lez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999;22:219\u201340. https:\/\/doi.org\/10.1146\/annurev.neuro.22.1.219.","journal-title":"Annu Rev Neurosci"},{"key":"467_CR108","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0197-4580(00)00181-0","volume":"22","author":"J Wegiel","year":"2001","unstructured":"Wegiel J, Wang KC, Imaki H, Rubenstein R, Wronska A, Osuchowski M, et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APPSW mice. Neurobiol Aging. 2001;22:49\u201361.","journal-title":"Neurobiol Aging"},{"key":"467_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"467_CR110","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0197-4580(01)00209-3","volume":"22","author":"M Stalder","year":"2001","unstructured":"Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 2001;22:427\u201334.","journal-title":"Neurobiol Aging"},{"key":"467_CR111","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2017.02.042","volume":"94","author":"JD Ulrich","year":"2017","unstructured":"Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer\u2019s disease. Neuron. 2017;94:237\u201348. https:\/\/doi.org\/10.1016\/j.neuron.2017.02.042.","journal-title":"Neuron"},{"key":"467_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener. 2018;13:1\u201316. https:\/\/doi.org\/10.1186\/s13024-018-0298-9.","journal-title":"Mol Neurodegener"},{"key":"467_CR113","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1084\/jem.20151948","volume":"213","author":"Y Wang","year":"2016","unstructured":"Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667\u201375. https:\/\/doi.org\/10.1084\/jem.20151948.","journal-title":"J Exp Med"},{"key":"467_CR114","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523\u20137. https:\/\/doi.org\/10.1038\/nature24016.","journal-title":"Nature"},{"key":"467_CR115","doi-asserted-by":"publisher","first-page":"e1475","DOI":"10.1371\/journal.pone.0001475","volume":"3","author":"D de Jong","year":"2008","unstructured":"de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, et al. No effect of one-year treatment with indomethacin on Alzheimer\u2019s disease progression: a randomized controlled trial. PLoS One. 2008;3:e1475. https:\/\/doi.org\/10.1371\/journal.pone.0001475.","journal-title":"PLoS One"},{"key":"467_CR116","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","volume":"58","author":"PS Aisen","year":"2002","unstructured":"Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer\u2019s disease. Neurology. 2002;58:1050\u20134. https:\/\/doi.org\/10.1212\/WNL.58.7.1050.","journal-title":"Neurology"},{"key":"467_CR117","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1212\/wnl.53.1.197","volume":"53","author":"S Scharf","year":"1999","unstructured":"Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease. Neurology. 1999;53:197\u2013201. https:\/\/doi.org\/10.1212\/wnl.53.1.197.","journal-title":"Neurology"},{"key":"467_CR118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jalz.2008.09.004","volume":"5","author":"CL Meinert","year":"2009","unstructured":"Group AR, Meinert CL, McCaffrey LD, Breitner JC. Alzheimer\u2019s disease anti-inflammatory prevention trial: design, methods, and baseline results. Alzheimers Dement. 2009;5:93\u2013104. https:\/\/doi.org\/10.1016\/j.jalz.2008.09.004.","journal-title":"Alzheimers Dement"},{"key":"467_CR119","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jalz.2010.12.014","volume":"7","author":"JC Breitner","year":"2011","unstructured":"Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer\u2019s disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7:402\u201311. https:\/\/doi.org\/10.1016\/j.jalz.2010.12.014.","journal-title":"Alzheimers Dement"},{"key":"467_CR120","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jalz.2012.11.012","volume":"9","author":"Group TADAPTR","year":"2013","unstructured":"Group TADAPTR. Results of a follow-up study to the randomized Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013;9:714\u201323. https:\/\/doi.org\/10.1016\/j.jalz.2012.11.012.","journal-title":"Alzheimers Dement"},{"key":"467_CR121","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.neurobiolaging.2017.02.012","volume":"54","author":"SE Perez","year":"2017","unstructured":"Perez SE, Nadeem M, He B, Miguel JC, Malek-Ahmadi MH, Chen K, et al. Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer\u2019s disease. Neurobiol Aging. 2017;54:133\u201343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.02.012.","journal-title":"Neurobiol Aging"},{"key":"467_CR122","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.molmed.2017.03.008","volume":"23","author":"FL Yeh","year":"2017","unstructured":"Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. Trends Mol Med. 2017;23:512\u201333.","journal-title":"Trends Mol Med"},{"key":"467_CR123","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Serrano JR, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114:11524\u20139. https:\/\/doi.org\/10.1073\/pnas.1710311114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"467_CR124","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1172\/JCI138179","volume":"130","author":"M Gratuze","year":"2020","unstructured":"Gratuze M, Leyns CEG, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest. 2020;130:4954\u201368.","journal-title":"J Clin Invest"},{"key":"467_CR125","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12264-013-1422-z","volume":"30","author":"E Dorey","year":"2014","unstructured":"Dorey E, Chang N, Liu QY, Yang Z, Zhang W. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer\u2019s disease. Neurosci Bull. 2014;30:317\u201330. https:\/\/doi.org\/10.1007\/s12264-013-1422-z.","journal-title":"Neurosci Bull"},{"key":"467_CR126","doi-asserted-by":"publisher","first-page":"44795","DOI":"10.1074\/jbc.M408127200","volume":"279","author":"FM Harris","year":"2004","unstructured":"Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase. Modulation by zinc. J Biol Chem. 2004;279:44795\u2013801. https:\/\/doi.org\/10.1074\/jbc.M408127200.","journal-title":"J Biol Chem"},{"key":"467_CR127","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA. 1997;278:1349. https:\/\/doi.org\/10.1001\/jama.1997.03550160069041.","journal-title":"JAMA"},{"key":"467_CR128","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki Y, Painter MM, Bu G, Kanekiyo T. Apolipoprotein E as a therapeutic target in Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30:773\u201389. https:\/\/doi.org\/10.1007\/s40263-016-0361-4.","journal-title":"CNS Drugs"},{"key":"467_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-019-1299-4","volume":"17","author":"M Safieh","year":"2019","unstructured":"Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer\u2019s disease. BMC Med. 2019;17:1\u201317. https:\/\/doi.org\/10.1186\/s12916-019-1299-4.","journal-title":"BMC Med"},{"key":"467_CR130","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","volume":"15","author":"T Williams","year":"2020","unstructured":"Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein e function in Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:8. https:\/\/doi.org\/10.1186\/s13024-020-0358-9.","journal-title":"Mol Neurodegener"},{"key":"467_CR131","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1017\/S1041610214000167","volume":"26","author":"HC Hendrie","year":"2014","unstructured":"Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A, et al. APOE \u03b54 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba. Int psychogeriatrcs. 2014;26:977\u201385. https:\/\/doi.org\/10.1017\/S1041610214000167.","journal-title":"Int psychogeriatrcs"},{"issue":"12","key":"467_CR132","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jalz.2019.07.016","volume":"15","author":"EE Blue","year":"2019","unstructured":"Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at APOE modifies Alzheimer\u2019s disease risk in Caribbean Hispanics. Alzheimers Dement. 2019;15(12):1524\u201332.","journal-title":"Alzheimers Dement"},{"key":"467_CR133","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein e, especially apolipoprotein E4, increases the oligomerization of amyloid \u03b2 peptide. J Neurosci. 2012;32:15181\u201392. https:\/\/doi.org\/10.1523\/JNEUROSCI.1542-12.2012.","journal-title":"J Neurosci"},{"key":"467_CR134","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00401-010-0666-1","volume":"119","author":"DZ Christensen","year":"2010","unstructured":"Christensen DZ, Schneider-Axmann T, Lucassen PJ, Bayer TA, Wirths O. Accumulation of intraneuronal A\u03b2 correlates with ApoE4 genotype. Acta Neuropathol. 2010;119:555\u201366. https:\/\/doi.org\/10.1007\/s00401-010-0666-1.","journal-title":"Acta Neuropathol"},{"key":"467_CR135","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","volume":"36","author":"MR Halliday","year":"2016","unstructured":"Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2016;36:216\u201327. https:\/\/doi.org\/10.1038\/jcbfm.2015.44.","journal-title":"J Cereb Blood Flow Metab"},{"key":"467_CR136","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1365-2990.2003.00457.x","volume":"29","author":"K Chalmers","year":"2003","unstructured":"Chalmers K, Wilcock GK, Love S. APOE \u025b4 influences the pathological phenotype of Alzheimer\u2019s disease by favouring cerebrovascular over parenchymal accumulation of A\u03b2 protein. Neuropathol Appl Neurobiol. 2003;29:231\u20138. https:\/\/doi.org\/10.1046\/j.1365-2990.2003.00457.x.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"467_CR137","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.neurobiolaging.2007.11.014","volume":"30","author":"MP Vitek","year":"2009","unstructured":"Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30:1350\u201360. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.11.014.","journal-title":"Neurobiol Aging"},{"key":"467_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:1\u201311. https:\/\/doi.org\/10.1038\/s41467-019-14279-8.","journal-title":"Nat Commun"},{"key":"467_CR139","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1161\/01.STR.0000014774.88027.22","volume":"33","author":"D Woo","year":"2002","unstructured":"Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33:1190\u20135. https:\/\/doi.org\/10.1161\/01.STR.0000014774.88027.22.","journal-title":"Stroke"},{"key":"467_CR140","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/nejm200001273420403","volume":"342","author":"HC O\u2019Donnell","year":"2000","unstructured":"O\u2019Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:240\u20135. https:\/\/doi.org\/10.1056\/nejm200001273420403.","journal-title":"N Engl J Med"},{"key":"467_CR141","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1212\/WNL.0b013e31829bfda4","volume":"81","author":"S Schilling","year":"2013","unstructured":"Schilling S, DeStefano AL, Sachdev PS, Choi SH, Mather KA, DeCarli CD, et al. APOE genotype and MRI markers of cerebrovascular disease. Neurology. 2013;81:292\u2013300. https:\/\/doi.org\/10.1212\/WNL.0b013e31829bfda4.","journal-title":"Neurology"},{"key":"467_CR142","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ana.410410607","volume":"41","author":"JAR Nicoll","year":"1997","unstructured":"Nicoll JAR, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotem E \u03b52 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41:716\u201321. https:\/\/doi.org\/10.1002\/ana.410410607.","journal-title":"Ann Neurol"},{"key":"467_CR143","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","volume":"72","author":"PT Nelson","year":"2013","unstructured":"Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708\u201315. https:\/\/doi.org\/10.1097\/NEN.0b013e31829a25b9.","journal-title":"J Neuropathol Exp Neurol"},{"key":"467_CR144","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/gim.2015.70","volume":"18","author":"JRM Black","year":"2016","unstructured":"Black JRM, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genet Med. 2016;18:283\u20139. https:\/\/doi.org\/10.1038\/gim.2015.70.","journal-title":"Genet Med"},{"key":"467_CR145","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1086\/301901","volume":"63","author":"CCW Klaver","year":"1998","unstructured":"Klaver CCW, Kliffen M, Van Duijn CM, Hofman A, Cruts M, Grobbee DE, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 1998;63:200\u20136. https:\/\/doi.org\/10.1086\/301901.","journal-title":"Am J Hum Genet"},{"key":"467_CR146","doi-asserted-by":"publisher","unstructured":"Arboleda-Velasquez JF, Lopera F, O\u2019Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; https:\/\/doi.org\/10.1038\/s41591-019-0611-3.","DOI":"10.1038\/s41591-019-0611-3"},{"key":"467_CR147","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"467_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000917","volume":"2","author":"LE Farrimond","year":"2012","unstructured":"Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer\u2019s disease: a systematic review. BMJ Open. 2012;2:e000917. https:\/\/doi.org\/10.1136\/bmjopen-2012-000917.","journal-title":"BMJ Open"},{"key":"467_CR149","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3233\/JAD-180766","volume":"67","author":"JL Cummings","year":"2019","unstructured":"Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer\u2019s disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67:779\u201394. https:\/\/doi.org\/10.3233\/JAD-180766.","journal-title":"J Alzheimers Dis"},{"key":"467_CR150","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210.","journal-title":"EMBO Mol Med"},{"key":"467_CR151","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14737175.2018.1531706","volume":"18","author":"F Panza","year":"2018","unstructured":"Panza F, Lozupone M, Solfrizzi V, Sardone R, Piccininni C, Dibello V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer\u2019s disease. Expert Rev Neurother. 2018;18:847\u201357. https:\/\/doi.org\/10.1080\/14737175.2018.1531706.","journal-title":"Expert Rev Neurother"},{"key":"467_CR152","doi-asserted-by":"publisher","first-page":"164","DOI":"10.14283\/jpad.2019.12","volume":"6","author":"S Gauthier","year":"2019","unstructured":"Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, et al. Combination therapy for Alzheimer\u2019s Disease: perspectives of the EU\/US CTAD Task Force. J Prev Alzheimers Dis. 2019;6:164\u20138. https:\/\/doi.org\/10.14283\/jpad.2019.12.","journal-title":"J Prev Alzheimers Dis"},{"key":"467_CR153","doi-asserted-by":"publisher","first-page":"e20202560","DOI":"10.1084\/JEM.20202560","volume":"218","author":"KD Rynearson","year":"2021","unstructured":"Rynearson KD, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P, et al. Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J Exp Med. 2021;218:e20202560. https:\/\/doi.org\/10.1084\/JEM.20202560.","journal-title":"J Exp Med"},{"key":"467_CR154","doi-asserted-by":"publisher","first-page":"164","DOI":"10.14283\/jpad.2015.85","volume":"3","author":"S Tomaszewski","year":"2016","unstructured":"Tomaszewski S, Gauthier S, Wimo A, Rosa-Neto P. Combination therapy of anti-Tau and anti-amyloid drugs for disease modification in early-stage Alzheimer\u2019s disease: socio-economic considerations modeled on treatments for tuberculosis, HIV\/AIDS and Breast Cancer. J Prev Alzheimers Dis. 2016;3:164\u201372. https:\/\/doi.org\/10.14283\/jpad.2015.85.","journal-title":"J Prev Alzheimers Dis"},{"key":"467_CR155","doi-asserted-by":"publisher","unstructured":"Salloway SP, Sevingy J, Budur K, Pederson JT, DeMattos RB, Von Rosenstiel P, et al. Advancing combination therapy for Alzheimer\u2019s disease. Alzheimer\u2019s Dement Transl Res Clin Interv. 2020;6:\u2013e12073. https:\/\/doi.org\/10.1002\/trc2.12073.","DOI":"10.1002\/trc2.12073"},{"key":"467_CR156","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/brain\/awaa438","volume":"144","author":"JL Robinson","year":"2021","unstructured":"Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer\u2019s disease. Brain. 2021;144:953\u201362. https:\/\/doi.org\/10.1093\/brain\/awaa438.","journal-title":"Brain"},{"key":"467_CR157","doi-asserted-by":"publisher","unstructured":"Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease. Brain. 2021; https:\/\/doi.org\/10.1093\/brain\/awab099.","DOI":"10.1093\/brain\/awab099"},{"key":"467_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM. \u03b1-Synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14:1\u201319. https:\/\/doi.org\/10.1186\/s13024-019-0320-x.","journal-title":"Mol Neurodegener"},{"key":"467_CR159","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Lev\u00e4lahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5.","journal-title":"Lancet"},{"key":"467_CR160","doi-asserted-by":"publisher","first-page":"e046951","DOI":"10.1002\/alz.046951","volume":"16","author":"LD Baker","year":"2020","unstructured":"Baker LD, Espeland MA, Kivipelto M, Whitmer RA, Snyder HM, Carrillo MC, et al. U.S. POINTER (USA). Alzheimers Dement. 2020;16:e046951. https:\/\/doi.org\/10.1002\/alz.046951.","journal-title":"Alzheimers Dement"},{"key":"467_CR161","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","volume":"16","author":"M Kivipelto","year":"2020","unstructured":"Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, et al. World-Wide FINGERS Network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078\u201394. https:\/\/doi.org\/10.1002\/alz.12123.","journal-title":"Alzheimers Dement"},{"key":"467_CR162","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","volume":"12","author":"SJB Vos","year":"2013","unstructured":"Vos SJB, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(13)70194-7.","journal-title":"Lancet Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-021-00467-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-021-00467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:31:48Z","timestamp":1672885908000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-021-00467-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s13024-021-00467-y","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<b>Dr. McDade,<\/b> is the Associate Director of the DIAN-TU. He reports serving on a Data Safety Committee for Eli Lilly and Company and Alector; scientific consultant for Eisai and Eli Lilly and Company; institutional grant support from Eli Lilly and Company, F. Hoffmann-La Roche, Ltd. and Janssen. <b>Dr. Morris,<\/b> is the Friedman Distinguished Professor of Neurology, Director, Knight ADRC; Associate Director of DIAN and Founding Principal Investigator of DIAN. He is funded by NIH grants # P30 AG066444; P01AG003991; P01AG026276; U19 AG032438; and U19 AG024904. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. <b>Dr. Holtzman,<\/b> is the Department Head of Neurology where the research is being conducted, is an inventor on patents for solanezumab, currently being tested in the DIAN-TU clinical trials. If solanezumab is approved as a treatment for Alzheimer\u2019s disease or dominantly inherited Alzheimer\u2019s disease, Washington University and Dr. Holtzman will receive part of the net sales of solanezumab from Eli Lilly and Company, which has licensed patents related to solanezumab from Washington University. <b>Dr. Bateman,<\/b> is the Director of the DIAN-TU and Principal Investigator of the DIAN-TU-001. He receives research support from the National Institute on Aging of the National Institutes of Health, DIAN-TU Trial Pharmaceutical Partners (Eli Lilly and Company, F. Hoffman-La Roche, Ltd., and Avid Radiopharmaceuticals), Alzheimer\u2019s Association, GHR Foundation, Anonymous Organization, DIAN-TU Pharma Consortium (Active: Biogen, Eisai, Eli Lilly and Company, Janssen, F. Hoffmann-La Roche, Ltd.\/Genentech. Previous: AbbVie, Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been an invited speaker, advisory board member and consultant for F. Hoffman La Roche, Ltd., an invited speaker and consultant for AC Immune and Janssen and a consultant for Amgen and Eisai. <b>Dr. Llibre-Guerra<\/b>, reports no conflict of interest relevant to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}